<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03514550</url>
  </required_header>
  <id_info>
    <org_study_id>Onko1</org_study_id>
    <nct_id>NCT03514550</nct_id>
  </id_info>
  <brief_title>Effects of Anesthesia on Immunity in Cancer</brief_title>
  <official_title>Immunomodulatory Effects of Volatile and Total Intravenous Anesthesia for Patients With Renal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is a comparative study of the cellular immunity response of patients
      operated on for kidney cancer under total intravenous and inhalational anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The severity of perioperative immunosuppression is directly proportional to the degree of
      surgical stress. A series of experimental and clinical studies indicate a different effect of
      certain types of anesthesia on immunity. It is believed that surgical stress itself opens an
      opportunity for the recurrence of oncological diseases precisely due to the immunosuppressive
      effect. The aim of present pilot clinical study is to test a hypothesis that total
      intravenous anesthesia as superior to inhalational anesthesia in term of its effects on cell
      immunity among patients with kidney cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD 16</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>NK cells expression of CD16 receptor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD45</measure>
    <time_frame>Baseline, end of surgery, postoperative days 1, 3-4, 7</time_frame>
    <description>CD45 expression on lymphocytes measured with flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD3</measure>
    <time_frame>Baseline, end of surgery, postoperative days 1, 3-4, 7</time_frame>
    <description>CD3 expression on lymphocytes measured with flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD19</measure>
    <time_frame>Baseline, end of surgery, postoperative days 1, 3-4, 7</time_frame>
    <description>CD19 expression on lymphocytes measured with flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4</measure>
    <time_frame>Baseline, end of surgery, postoperative days 1, 3-4, 7</time_frame>
    <description>CD4 expression on lymphocytes measured with flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8</measure>
    <time_frame>Baseline, end of surgery, postoperative days 1, 3-4, 7</time_frame>
    <description>CD8 expression on lymphocytes measured with flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD16</measure>
    <time_frame>Baseline, end of surgery, postoperative days 1, 3-4, 7</time_frame>
    <description>CD16 expression on lymphocytes measured with flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD25</measure>
    <time_frame>Baseline, end of surgery, postoperative days 1, 3-4, 7</time_frame>
    <description>CD25 expression on lymphocytes measured with flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HLA-DR</measure>
    <time_frame>Baseline, end of surgery, postoperative days 1, 3-4, 7</time_frame>
    <description>HLA-DR expression on lymphocytes measured with flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Surgery</condition>
  <condition>Renal Cancer</condition>
  <arm_group>
    <arm_group_label>total intravenous anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and propofol for perioperative anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volatile anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and sevoflurane for perioperative anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol will be used for anesthesia during surgery</description>
    <arm_group_label>total intravenous anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Sevoflurane will be used for anesthesia during surgery</description>
    <arm_group_label>Volatile anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Epidural block</intervention_name>
    <description>Epidural catheterization Th9-Th10, ropivacaine for perioperative analgesia</description>
    <arm_group_label>total intravenous anesthesia</arm_group_label>
    <arm_group_label>Volatile anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Surgery for renal cancer

          -  Signed informed concent

        Exclusion Criteria:

          -  Propofol or sevoflurane intolerance

          -  Contraindications for epidural anesthesia

          -  Renal failure

          -  Hepatic failure

          -  Congestive heart failure

          -  Previous hemotherapy

          -  Hematological diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sergey Efremov, MD, PhD</last_name>
    <phone>79137946090</phone>
    <email>sergefremov@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>State Research Institute of Circulation Pathology</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey Efremov, MD, PhD</last_name>
      <phone>7 913 794 6090</phone>
      <email>sergefremov@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Vladimir Lomivorotov, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergey Efremov, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gleb Moroz, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marat Abubakirov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Shilova, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victoria Kozireva, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergey Yarmoshuk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2018</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Meshalkin Research Institute of Pathology of Circulation</investigator_affiliation>
    <investigator_full_name>Efremov Sergey</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

